Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2450
+0.0028 (1.16%)
At close: Jun 27, 2025, 4:00 PM
0.2350
-0.0100 (-4.08%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 506 employees as of December 31, 2024. The number of employees increased by 57 or 12.69% compared to the previous year.
Employees
506
Change (1Y)
57
Growth (1Y)
12.69%
Revenue / Employee
$355,018
Profits / Employee
-$138,132
Market Cap
64.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADAP News
- 6 weeks ago - Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Adaptimmune Reports Q1 Financial Results and Provides Business Update - Newsfile Corp
- 7 weeks ago - Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 - Newsfile Corp
- 3 months ago - Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Adaptimmune Provides Q4 and Full Year 2024 Business Update - Newsfile Corp
- 3 months ago - Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 - Newsfile Corp
- 5 months ago - Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile Corp
- 5 months ago - Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) - Newsfile Corp